You are here: Industry Insights > Japan

News List

Evidera, CSS to Develop Patient-Centered Research Capabilities in Japan contractpharma
August 22, 2019
Focus on creating a more complete geographic customer solution for patient-centered research.
Marken Acquires Japanese Logistics Company contractpharma
August 02, 2019
Acquisition of PCX expands the company's footprint in Japan.
Scientists in Japan develop prosthetics for retinal stimulation biospectrumasia
July 29, 2019
OUReP is a photoelectric dye-coupled thin film device that generates electric potential changes when exposed to light
PRA Health Sciences Buys Out Joint Venture in Japan contractpharma
July 25, 2019
Acquires expert staff members from Takeda.
INTERPHEX Japan puts up an impressive show biospectrumasia
July 04, 2019
INTERPHEX JAPAN is Japan's largest and Asia's leading exhibition for pharmaceutical manufacturing and packaging technologies. Including concurrent pharma technology exhibitions, 1,280 exhibitors have gathered from all over Asia.
VANFLYTA® Receives Approval in Japan americanpharmaceuticalreview
June 20, 2019
Daiichi Sankyo announced the Ministry of Health, Labor and Welfare (MHLW) of Japan has approved VANFLYTA® (quizartinib), an oral FLT3 inhibitor, for the treatment of adult patients with relapsed/refractory FLT3-ITD acute myeloid leukemia (AML), as detecte
Japan first to approve Roche’s tumour-agnostic medicine Rozlytrek pharmaceutical-technology
June 20, 2019
Japan approves Roche’s personalised medicine Rozlytrek. Credit: © 2015 F. Hoffmann-La Roche.
Japan becomes the first country to approve Roche's personalised medicine Rozlytrek worldpharmanews
June 20, 2019
Japan becomes the first country to approve Roche's personalised medicine Rozlytrek.
Japan the first to approve Roche’s personalised medicine Rozlytrek biospectrumasia
June 19, 2019
First tumour-agnostic medicine approved in Japan for adult and paediatric patients with NTRK fusion-positive advanced recurrent solid tumours
Japan First to Approve Roche’s Rozlytrek contractpharma
June 19, 2019
A tumor-agnostic medicine for treatment of adult and pediatric patients with NTRK fusion-positive advanced recurrent solid tumors/

Previous page 1 2 3 4 5 6 7 8 9 10 11 Next page